KIO-301, a Candidate for Retinitis Pigmentosa Treatment
Chongkundang Responsible for Domestic Development, Approval, and Commercialization

Chongkundang announced on the 21st that it has signed a license agreement with the U.S.-based ophthalmology-focused pharmaceutical company Kiora Pharmaceuticals for the domestic development and commercialization of the new drug candidate "KIO-301" for retinal indications.


Under the agreement, Chongkundang will be responsible for the domestic development, regulatory approval, and commercialization of KIO-301. Kiora will receive milestone payments based on the development and approval stages and royalties from sales in Korea.

Kim Youngjoo, CEO of Chongkundang (left), and Brian Strem, CEO of Kiora Pharmaceuticals, are posing for a commemorative photo after signing a license agreement for the development and commercialization of the retinal pigmentosa treatment drug candidate ‘KIO-301’ at Chongkundang headquarters in Seodaemun-gu, Seoul. Chongkundang

Kim Youngjoo, CEO of Chongkundang (left), and Brian Strem, CEO of Kiora Pharmaceuticals, are posing for a commemorative photo after signing a license agreement for the development and commercialization of the retinal pigmentosa treatment drug candidate ‘KIO-301’ at Chongkundang headquarters in Seodaemun-gu, Seoul. Chongkundang

View original image

KIO-301 is a small-molecule new drug candidate under development as a treatment for retinitis pigmentosa, a rare hereditary retinal disease. Retinitis pigmentosa is a disorder in which photoreceptors, the cells that detect light, gradually degenerate, leading to progressive narrowing of the field of vision and declining visual acuity; it is estimated that there are more than 10,000 patients with this condition in Korea.


KIO-301 is being developed to grant light-sensing capabilities to retinal ganglion cells that remain after photoreceptor degeneration. It is designed to act independently of specific gene mutations, which means it also has the potential to expand its indications to other hereditary retinal diseases beyond retinitis pigmentosa, such as choroideremia and Stargardt disease.


Kim Youngjoo, CEO of Chongkundang, stated, "KIO-301 is a new drug candidate with a novel mechanism that is not limited by specific gene mutations. Based on our expertise in ophthalmology and our clinical and regulatory capabilities, we plan to work with Kiora and our global partners to pursue domestic development."



Brian Strum, President and CEO of Kiora Pharmaceuticals, said, "With this agreement, the development and commercialization network for KIO-301 now extends to Korea, following the United States, Europe, Japan, and China. Through collaboration with Chongkundang, we aim to efficiently advance KIO-301 into global Phase 3 clinical trials and offer new treatment options to patients with retinitis pigmentosa in Korea."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing